Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | PTPRF | P10586 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | PTPRB | P23467 | 1/20 | 0.53 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207901 | 1.00 | AKR1B1 (0.59) | AKR1B1HPGDMAPK1ENPP2PIM1 | |
| SCHEMBL4209066 | 0.85 | MAPK1 (0.55) | AKR1B1MAPK1ENPP2PIM1MAOA | |
| SCHEMBL4209071 | 0.85 | MAPK1 (0.55) | AKR1B1MAPK1ENPP2PIM1MAOA | |
| SCHEMBL15817009 | 0.81 | MAPK1 (0.78) | HPGDMAPK1MAOAMAOBCA9 | |
| SCHEMBL15817005 | 0.81 | MAPK1 (0.78) | HPGDMAPK1MAOAMAOBCA9 | |
| SCHEMBL15817003 | 0.81 | MAPK1 (0.78) | HPGDMAPK1MAOAMAOBCA9 | |
| SCHEMBL4215334 | 0.81 | KDM4E (0.55) | AKR1B1MAPK1ENPP2PIM1CA9 | |
| SCHEMBL4828044 | 0.81 | KDM4E (0.55) | AKR1B1MAPK1ENPP2PIM1CA9 | |
| SCHEMBL20534357 | 0.76 | AKR1B1 (0.78) | AKR1B1PTPN1CA9 | |
| SCHEMBL20534356 | 0.76 | AKR1B1 (0.78) | AKR1B1PTPN1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501509-A4 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-7348348-B2 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK & CO. INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
| EP-1501509-A2 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004024061-A2 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | KCNN1, KCNH1, KCNN2 | AKR1B1 1549/4885HPGD 2151/4885MAPK1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.